Peak Risk of Recurrence Occurs during the First Two Years after a Pancreatectomy in Patients Receiving Neoadjuvant FOLFIRINOX

SIMPLE SUMMARY: No codified/systematic surveillance program exists for borderline/locally advanced pancreatic ductal carcinoma treated with neoadjuvant FOLFIRINOX and secondary resection. This study aimed to determine the trend of recurrence in patients who were managed using such a treatment strate...

Descripción completa

Detalles Bibliográficos
Autores principales: Alfano, Marie-Sophie, Garnier, Jonathan, Palen, Anaïs, Ewald, Jacques, Piana, Gilles, Poizat, Flora, Mitry, Emmanuel, Delpero, Jean-Robert, Turrini, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649429/
https://www.ncbi.nlm.nih.gov/pubmed/37958326
http://dx.doi.org/10.3390/cancers15215151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649429/
https://www.ncbi.nlm.nih.gov/pubmed/37958326
http://dx.doi.org/10.3390/cancers15215151

Ejemplares similares